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ABSTRACT
Objectives: The first aim of the study (i) assess the current asthma status of general-practitioner-
managed patients receiving regular fixed-dose combination inhaled corticosteroid and long-acting
beta2 agonist (FDC ICS/LABA) therapy and (ii) explore patients’ perceptions of asthma control and
attitudes/behaviors regarding preventer inhaler use. Methods: A cross-sectional observational study
of Australian adults with a current physician diagnosis of asthma receiving 2 prescriptions of FDC
ICS/LABA therapy in the previous year, who were recruited through general practice to receive a
structured in-depth asthma review between May 2012 and January 2014. Descriptive statistics and
Chi-Square tests for independence were used for associations across asthma control levels. Results:
Only 11.5%of the patients had controlled asthmabased onguideline-defined criteria. Contrarily, 66.5%
of the patients considered their asthma to be well controlled. Incidence of acute asthma exacerba-
tions in the previous year was 26.5% and 45.6% of the patients were without a diagnosis of rhinitis.
Asthma medication use and inhaler technique were sub-optimal; only 41.0% of the preventer users
reported everyday use. The side effects of medication were common and more frequently reported
among uncontrolled and partially controlled patients. Conclusions: The study revealed the extent to
which asthma management needs to be improved in this patient cohort and the numerous unmet
needs regarding the current state of asthma care. Not only there is a need for continuous education
of patients, but also education of health care practitioners to better understand the way in which
patient’s perceptions impact on asthmamanagement practices, incorporating these findings into clin-
ical decision making.
Introduction
Asthma is a common episodic respiratory disease and
remains a major human and economic burden globally
[1]. In Australia, asthma affects 10% of the population
and in 2015, the estimated direct costs from hospitali-
sations, treatment and health care utilisation were $1.2
billion and indirect costs from disability and premature
death were $24.7 billion [2,3]. Despite the advances in
our understanding of the disease, the availability of effec-
tive treatments and the development of international and
national guidelines [4,5] to help optimise the manage-
ment of asthma and improve patient outcomes, asthma
remains poorly controlled.
CONTACT Sinthia Bosnic-Anticevich sinthia.bosnic-anticevich@sydney.edu.au Woolcock Institute of Medical Research, Quality Use of Respiratory
Medicines Group,  Glebe Point Road Glebe, NSW  Australia Glebe, New South Wales  Australia.
Colour versions of one or more of the figures in the article can be found online at www.tandfonline.com/ijas.
Poorly controlled asthma creates a greater economic
burden on individuals, communities and health care
systems and controlled disease [6]. Poor asthma control
is associated with an increased risk of exacerbations,
diminished quality of life, debilitation, reduced pro-
ductivity and increased health care utilisation [7–9].
Furthermore, poor asthma control and history of exac-
erbations are among the risk factors for future asthma
exacerbations [4–6]. Other risk factors include poor
inhaler technique and poor adherence [6]. Poor asthma
control may be attributed to a broad range of inter-related
factors many of which stem from patients having poor
asthma knowledge, inadequate understanding of their
©  Sinthia Bosnic-Anticevich, Vicky Kritikos, Victoria Carter, Kwok Yin Yan, Carol Armour, Dermot Ryan, and David Price. Published with license by Taylor & Francis.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-
ncnd/./), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built
upon in any way.
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2 S. BOSNIC-ANTICEVICH ET AL.
therapy or misconceived health beliefs due to insufficient
asthma education [10,11]. This, in turn, may reflect
poor knowledge and skills of the health care professional
(HCP) [12].
Over the past decade, a number of multinational
surveys have shown that asthma control, when measured
by various instruments, remains sub-optimal [13–20].
Several international ‘real-life’ clinical studies conducted
in general practice and hospital outpatient clinics have
also shown that poor asthma control is prevalent, despite
the availability of treatments [21–23]. More recently, the
European Recognise Asthma and LInk to Symptoms and
Experience (REALISE) survey [24] and the REALISE
Asia survey [25] have confirmed that asthma control
continues to remain poor, with many patients perceiving
their asthma to be trivial and well controlled despite
the presence of symptoms and exacerbations. In part,
this may be due to low patient expectations [26,27]. In
Australia, apart from a recent population-based online
survey reporting poor asthma control in 45.3% of the
participants [20], little is known about the asthma control
status of adults with a current diagnosis of asthma who
are prescribed fixed-dose combination inhaled corticos-
teroid and long-acting beta2 agonist (FDC ICS/LABA)
therapy in primary care. FDC ICS/LABA therapy is rec-
ommended for moderate–severe asthma (as represented
by step 3or above in international and national guide-
lines) [4,5], and is reported to have been prescribed in
49.5% of the GP encounters for asthma among Australian
adults in 2011 [3].We hypothesised that the asthma status
of adults with a current physician diagnosis of asthma
who are considered to have moderate–severe asthma
and are treated appropriately, is poor, and that there are
several patient-related factors that contribute to this.
The study aimed to measure the current asthma
status of general practitioner (GP)-managed patients
with moderate–severe asthma-prescribed regular FDC
ICS/LABA therapy and to explore patient attitudes and
behaviours regarding asthma medication use. This study
was part of an international initiative conducted in seven
European countries; implementing Helping Asthma in
Real-life Patients (iHARP) among 5000 patients with
moderate–severe asthma who are managed in a real-life
setting to help optimise asthmamanagement and improve
patient outcomes. Here, we report the Australian data
from the iHARP initiative. The specific objectives of the
study were to:
i. assess asthma symptoms, indicators of acute
exacerbations, levels of guideline-defined asthma
control, inhaler device technique and rhinitis
symptoms and treatment use;
ii. investigate patients’ perceptions of asthma control
in relation to their guideline-defined level of con-
trol and history of asthma exacerbations;
iii. explore patient attitudes and behaviours regarding
preventer inhaler use;
iv. examine associations between guideline-defined
control and asthma symptoms, indicators of acute
exacerbations, rhinitis symptoms, patterns of pre-
venter inhaler use, and side effects from inhaled
preventer medication.
Methods
Study design
This study took the form of a cross-sectional observa-
tional study conducted on a sample of general practice
patients enrolled to receive a comprehensive structured
review of their asthma between May 2012 and January
2014.
Participants and setting
A convenience sample of GP practices from the Sydney
metropolitan area was approached to participate in the
study. Their involvement in this study required GPs to
identify asthma patients from the practice database who
fulfilled the inclusion criteria based on their medical
records. General practice managers then sent eligible
patients a letter inviting them to participate in this
study and undergo a pharmacist-led structured in-depth
asthma review in the general practice setting. Patients
who agreed to participate were asked to contact their GP
practice to organise a time for a single 45-minute review
visit during the specified period the specialist asthma
pharmacist was available. Patients were asked to bring
along their asthma medications and devices to the review
visit. During the asthma review, data collected were
entered by the pharmacist into an electronic database.
At the end of the review, patients received appropriate
education from the pharmacist and were encouraged to
make a follow-up appointment with their GP to discuss
the findings of the review. Each GP practice received an
identical asthma review service.
Inclusion and exclusion criteria
Patients were included into the study if all the following
criteria were met: they were aged 18–71 years at the time
of the review, they had a current physician diagnosis
of asthma, and they had received 2 prescriptions for
FDC ICS/LABA medication in the previous 12 months.
Patients were excluded from the study if they had a
diagnosis of chronic obstructive pulmonary disease
(COPD) or any other chronic respiratory disease other
than asthma documented in their medical records, or
were aged 40 years with a history of smoking and no
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JOURNAL OF ASTHMA 3
documentary evidence that COPD has been excluded
either by spirometry or the International Primary Care
Respiratory Group (IPCRG) recognised differential diag-
nosis questionnaire [28]. Patients were also excluded
if they had received oral steroids and/or antibiotics for
a lower respiratory condition in the two weeks pre-
ceding the review visit or they had received long-term
systemic treatments for asthma including oral steroid,
theophylline, leukotriene receptor antagonist or anti-IgE
therapy. These exclusions were specified to minimise any
potential confounding on disease stability and control by
additional medications.
Sample size
Reviews of at least 196 asthma patients were needed in
order to ensure that the results were generalisable to GP-
managed Australian adults with asthma receiving FDC
ICS/LABA therapy. This recruitment target was calcu-
lated based on the number of Medicare GP consultations
claimed in 2010–2011 for asthma in Australia (approxi-
mately 2.64 million), within a 7% margin of error at 95%
confidence interval [29].
Asthma review
The asthma review used questionnaire-led and
pharmacist-led assessments to collect information about
patient demographic and clinical characteristics, asthma
symptoms, rhinitis symptoms, inhaler technique, and
occurrence of exacerbations requiring a short course
of oral steroid use in the previous 12 months. Asthma
control was assessed using the four GINA criteria, which
asked patients if they experienced the following dur-
ing the previous week: daytime symptoms (more than
twice/week), any night wakening due to asthma, need
reliever inhaler (more than twice/week), and any lim-
itation in daytime activity. The presence of these four
criteria determined the asthma symptom control cate-
gory as follows: none of the above (controlled), 1 or 2 of
the above (partially controlled), and 3 or 4 of the above
(uncontrolled) [30]. Exacerbations were identified by
one of the following patient-reported outcomes: hospital
admission with breathing or chest problems, accident or
emergency attendance related to asthma, or a short-term
course (5–10 days) of oral steroids for worsening asthma.
The number of exacerbations was taken from the 12-
month period preceding the asthma review. Self-reported
rhinitis symptoms were assessed with a single question
derived from the Allergic Rhinitis and its Impact on
Asthma and IPCRG definition of rhinitis [31,32]; ‘Do
you have any of these symptoms: itchy, runny, blocked nose
or sneezing when you don’t have a cold?’, with responses
ranging from, 0 (‘no’), 1 (‘occasionally and little bother’),
2 (‘occasionally but quite a bother’), 3 (‘most days but little
bother’), or 4 (‘most days and a lot of bother’). Responses
1 and 3 were classified under ‘mild’ rhinitis and responses
2 and 4 were classified under ‘moderate–severe’ rhinitis.
Appendix A lists the questions (derived from various
sources) included in the structured asthma review [31–
35]. Self-reported intranasal corticosteroid (INCS) and
oral antihistamine use for the treatment of rhinitis were
recorded. Inhaler techniquewas assessed, and the number
and type of error were recorded for each inhaler device
against predefined checklists developed by a steering
committee of experts in the field [36]. This technique was
assessed by the pharmacist, who had received training in
the identification of inhaler technique errors.
Ethics and consent
This study was approved by the University of Sydney
Human Research Ethics Committee (Protocol Number
2012/967). All participants provided informed consent.
Approval for use of the electronic database was granted by
the Anonymised Data Ethics Protocols and Transparency
committee and registered on the European Network of
Centres for Pharmacoepidemiology and Pharmacovigi-
lance (ENCEPP) (as ENCePP/SDPP/9651).
Data analysis
Data collectedwere de-identified and analysed using SPSS
(IBM R© SPSS R© Statistics) Version 22. Descriptive statis-
tics were used to summarise patient demographics and
clinical characteristics. The perception of asthma control
was analysed by the GINA-defined control level and his-
tory of exacerbations using descriptive statistics. The rela-
tionship betweenGINA-defined control and incidences of
asthma symptoms, indicators of acute exacerbations, inci-
dence of rhinitis symptoms, patterns of preventer inhaler
use and side effects from inhaled preventer medication
was assessed using the Chi-Square test for independence.
A significance level of p< 0.05 was used for all statistical
procedures.
Results
Patient population
Of the nine GP practices approached, six agreed to par-
ticipate in the study (participation rate, 66.7%). A total of
370 patients whomet the inclusion criteria were identified
by GPs from their practice databases and were invited to
participate in the study. Of the 370 invited patients, the
first 200 patients who agreed to participate were recruited
into the study and underwent a pharmacist-led structured
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4 S. BOSNIC-ANTICEVICH ET AL.
Table . Patient demographics and clinical characteristics.
Patients
(N = )
Female, n (%)  (.)
Age in years, mean (SD) . (.)
Age range, years, n (%)
–  (.)
–  (.)
 or more  (.)
Years since asthma diagnosis, n (%)
–  (.)
–  (.)
 or more  (.)
BMI category, n (%)
Underweight (BMI< .)  (.)
Normal (BMI .–.)  (.)
Overweight (BMI –.)  (.)
Obese (BMI )  (.)
Highest level of education category, n (%)
Year  or below  (.)
Year –  (.)
Certificate or diploma  (.)
University degree  (.)
Smoking history, n (%)
Never smoked  (.)
Past smoker  (.)
Current smoker  (.)
Comorbidities,
a
n (%)
Rhinitis  (.)
Eczema  (.)
Gastro-oesophageal reflux disease  (.)
Hypertension  (.)
Diabetes  (.)
Cardiac disease  (.)
Fixed-dose combination treatment type, n (%)
Budesonide/eformoterol Turbuhaler  (.)
Fluticasone/salmeterol Metered Dose Inhaler  (.)
Fluticasone/salmeterol Accuhaler  (.)
Notes. Figures represent number (%) of patients or mean (SD).
aSelf-reported by patients as having been diagnosed by a doctor, in response
to the question: ‘Do you have a diagnosis of any of the following conditions?’
in-depth asthma review. Patient demographics and clini-
cal characteristics are shown in Table 1. The mean age of
patients was 47.7 (±15.8) years, 128 (64.0%)were females,
165 (82.5%) had been diagnosed with asthma for more
than 10 years, 69 (34.5%) were obese (i.e., had a BMI 
30) and 28 (14.0%) were current smokers.
Asthma control
Overall, 23 (11.5%) patients had controlled asthma
according to the GINA criteria, 77 (38.5%) had par-
tially controlled asthma and 100 (50.0%) had uncon-
trolled asthma (Table 2). Over half of the patients (52.5%)
had symptoms that interfered with daily activities, 114
(43.0%) had symptoms affecting their sleep and 106
(53.0%) had used their relievers three or more times
in the week before the asthma review visit. Overall, 53
(26.5%) patients reported having used at least one short-
term course of oral steroids for asthma in the previous
12 months, 54 (27.0%) reported having taken at least
one day off work/education due to asthma, 23 (11.5%)
reported having visited an emergency department and
12 (6.0%) reported having been hospitalised for asthma
(Table 2).
Asthma symptoms and exacerbations across control
levels
Incidences of asthma symptoms and indicators of exacer-
bations across asthma control levels are shown in Table 2.
Compared to patients with controlled asthma, those with
uncontrolled asthma were more likely to have experi-
enced acute exacerbations requiring short-term courses
of oral steroids (13.0% vs. 40.0%, p < 0.001), have taken
time off work/education due to asthma (17.4% vs. 40.0%,
p< 0.001), or have been hospitalised due to asthma (8.7%
vs. 10.0%, p = 0.018) in the 12 months before the asthma
review visit.
Perception of asthma control
Overall, 133 (66.5%) patients considered their asthma
to be well controlled in the past four weeks when in
fact only 23 (11.5%) patients had asthma that was cur-
rently controlled according to GINA criteria (Table 3).
Almost half of the patients (49.0%) with currently uncon-
trolled asthma according to GINA criteria considered
their asthma to be well controlled. Of 133 patients who
considered their asthma well controlled, 61 (45.9%) had
used reliever medications more than twice a week, 52
(39.1%) had symptoms that interfered with normal activ-
ities and 39 (29.3%) had awoken at night due to asthma in
the previous week. Moreover, almost half of the patients
who had required oral steroid use and over one-third of
those who had experienced acute exacerbations requir-
ing emergency department visits or hospitalisations in the
previous year regarded their asthma as well controlled
(Table 3).
Rhinitis symptoms across control levels and
treatment use
Incidences of rhinitis symptoms overall and across GINA-
defined asthma control levels are shown inFigure 1.While
180 (90.0%) patients reported having rhinitis symptoms,
with 104 (57.8%) and 76 (42.2%) patients classified as
having moderate–severe and mild rhinitis, respectively,
82 (45.6%) patients were without a diagnosis. A higher
proportion of patients with uncontrolled asthma had
moderate–severe rhinitis symptoms than those with con-
trolled asthma (61.8% vs. 43.4%, p = 0.025). Among the
patients reporting rhinitis symptoms, 85 (47.2%) reported
using oral antihistamines and 47 (26.1%) INCSs. How-
ever, 70 (67.3%) patients with moderate–severe rhinitis
were not using the recommended INCS therapy.
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JOURNAL OF ASTHMA 5
Table . Indicators of asthma symptoms and exacerbations overall and by GINA-defined control levels.
GINA-defined asthma control
Overall (N = ) Controlled (n = ) Partially controlled (n = ) Uncontrolled (n = ) p Valuec
Control and indicators of symptoms
Days with symptoms
a
None  (.)  (.)  (.)  <.
– days  (.)  (.)  (.)  (.)
 days  (.)   (.)  (.)
Normal activities affected by symptoms
a
None  (.)  ()  (.)  (.) <.
 day  (.)   (.)  (.)
Nighttime awakening
a
None  (.)  ()  (.)  (.) <.
 day  (.)   (.)  (.)
Reliever inhaler use
a
None  (.)  (.)  (.)  (.) <.
– days  (.)  (.)  (.)  (.)
 days  (.)   (.)  (.)
Acute exacerbations
Oral steroid use for worsening asthma
b
 (.)  (.)  (.)  (.) <.
 course  (.)  (.)  (.)  (.)
Days off work/education due to asthma
b
None  (.)  (.)  (.)  (.) <.
 day  (.)  (.)  (.)  (.)
Emergency department visit due to asthma
b
None  (.)  (.)  (.)  (.) .
 visit  (.)  (.)  (.)  (.)
Hospitalisation due to asthma
b
None  (.)  (.)  (.)  (.) .
 stay  (.)  (.)   (.)
Notes. Data are shown as n (%) of patients.
GINA; Global Initiative for Asthma.
aIn the previous  days.
bIn the previous  months.
cp value from Chi-Square test.
Attitudes and behaviours regarding preventer
inhaler use and side effects
While the majority of patients (85.5%) stated that they
found their preventer inhaler(s) easy to use and 146
(73.0%) felt that they had a ‘good’ or ‘excellent’ inhaler
technique, an objective assessment of inhaler technique
revealed that all 200 patients exhibited at least two errors
and 114 (72.0%) exhibited five or more errors. The five
most common errors performed included the following:
does not have head tilted such that the chin is slightly
upwards (93.5%), does not breathe out to empty lungs
(88.5%), no breath-hold (or holds breath for less than
3 seconds) (88.5%), inappropriate inhalation technique
(78.0%), and second dose within 30 seconds (37.0%).
Only 82 (41.0%) of the FDC preventer medication users
reported taking it everyday, 54 (27.0%) used it only when
they had symptoms and 46 (23.0%) used it for some days;
12 (6.0%) had stopped taking it and six (3.0%) never took
it at all (Figure 2). Compared to patients with controlled
asthma, those with uncontrolled asthma were more likely
Table . Perception of asthma control for the overall population and by GINA-defined control levels and history of exacerbations.
GINA-defined asthma control Acute exacerbationsa
Overall (N = )
Controlled
(n = )
Partially
controlled
(n = )
Uncontrolled
(n = )
Oral steroid
(n = )
Emergency
department visits
(n = )
Hospitalisations
(n = )
Perception of asthma
control
Not well controlled  (.)  (.)  (.)  (.)  (.)  (.)  (.)
Well controlled  (.)  (.)  (.)  (.)  (.)  (.)  (.)
Notes. Data are shown as n (%) of patients.
GINA; Global Initiative for Asthma.
aAt least one in the previous  months due to asthma.
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6 S. BOSNIC-ANTICEVICH ET AL.
Figure . Incidence of rhinitis symptoms overall and by GINA-
defined control levels. GINA; Global Initiative for Asthma. Self-
reported rhinitis symptoms by patients, in response to the ques-
tion: ‘Do you have any of these symptoms: itchy, runny, blocked
nose or sneezing when you don’t have a cold?’ with responses
ranging from,  (no),  (occasionally and little bother),  (occasion-
ally but quite a bother),  (most days but little bother), or  (most
days and a lot of bother). Responses  and  were classified under
‘mild’ rhinitis symptoms and responses  and  under ‘moderate–
severe’ rhinitis symptoms. Patients classified as having mild symp-
toms: n = ; moderate–severe symptoms: n = ; Global Ini-
tiative for Asthma-defined controlled: n = ; partially controlled:
n = ; uncontrolled: n = ).
to take their preventermedications only on some days but
not on others (13.0%vs. 30.0%, p= 0.029). Themost com-
mon reasons selected for non-adherence included feel-
ing worried about taking regular preventer medication
(52.5%), forgetting to take it (46.0%) or just deciding to
miss a dose (41.0%).
The rate of reported side effects experienced from the
preventer inhaler use was high with 155 (77.5%) patients
reporting that they had experienced at least one side effect
(Figure 3), with 24 (12.0%) experiencing a maximum of
four side effects. Incidences of side effects experienced
from preventer medication use overall and by GINA-
defined control levels are shown in Figure 4. Compared to
Figure . Patterns of preventer medication use overall and by
GINA-defined control levels. GINA; Global Initiative for Asthma.
Self-reported pattern of preventer medication use by patients, in
response to the question: ‘Which statement best describes how
you take your regular asthma treatment?’ with the above five
options. Patients taking a preventer inhaler (overall; N = ;
Global Initiative for Asthma-defined controlled: n = ; partially
controlled: n = ; uncontrolled: n = ).
Figure . Number of side effects experienced from preventer
inhaler use overall and by GINA-defined control levels. GINA;
Global Initiative for Asthma. Side effects experienced by patients
from preventer inhaler use, in response to the question: ‘Do you
experience any of these side effects from your preventer inhaler?’
with ‘yes’ or ‘no’ responses for the following side effects: contin-
ual sore mouth/throat; oral thrush; bruising; hoarse voice; abnor-
mal weight gain and cough. Patients could indicatemore than one
side effect. Patients using a preventer inhaler (overall; N = ;
Global Initiative for Asthma-defined controlled: n = ; partially
controlled: n = ; uncontrolled: n = ).
patients with controlled asthma, those with uncontrolled
and partially controlled asthma were more likely to have
experienced at least one side effect (47.8% vs. 83.0% and
79.2%, p = 0.001). In the past year, 190 (95.0%) patients
had not had their inhaler technique checked by an HCP.
Overall, 28 (14.0%) patients had seen a respiratory spe-
cialist for asthma outside the GP practice in the past year,
with 91 (45.5%) having seen a specialist more than a year
ago and 81 (40.5%) never having seen a specialist outside
the practice.
Figure . Incidences of side effects from preventer inhaler use
overall and by GINA-defined control levels. GINA; Global Initia-
tive for Asthma. Self-reported side effects of preventer inhaler
use by patients, in response to the question: ‘Do you experi-
ence any of these side effects from your preventer inhaler?’ with
‘yes’ or ‘no’ responses for the following side effects: continual
sore mouth/throat; oral thrush; bruising; hoarse voice; abnormal
weight gain and cough. Patients could indicate more than one
side effect. Patients using a preventer inhaler (overall; N = ;
Global Initiative for Asthma-defined controlled: n = ; partially
controlled: n = ; uncontrolled: n = ).
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Discussion
This study provided a unique ‘snapshot’ of the current
asthma status of GP-managed patients receiving fixed-
dose combination therapy, and insights into patient’s per-
ceptions, attitudes and behaviour regarding preventer
inhaler use. Our findings showed that the incidence of
controlled asthma was low with a high risk of future
asthma exacerbations, and a discrepancy between per-
ceived and guideline-defined level of asthma symptom
control. Undiagnosed and undertreated comorbid rhini-
tis was prevalent and asthma medication use was sub-
optimal. Inhaler technique continues to be a major issue
and medication concerns as well as not perceiving the
importance of taking medication remain problematic.
The side effects of medication were common and more
frequently reported in patients with sub-optimal con-
trol. Taken together, the results from this study revealed
the extent to which asthma management needs to be
improved in this group of patients and highlights the
numerous unmet needs regarding the current state of
asthma care. This research provided valuable insight by
utilising a structured in-depth asthma review approach
and helped in identifying populations that should be tar-
geted by tailored interventions to improve asthma man-
agement practices in the future.
The strength of this study lies in the fact that it is the
first Australian cross-sectional observational study pro-
viding data on detailed assessment of asthma symptoms,
indicators of acute exacerbations and levels of guideline-
defined control among GP-managed patients receiving
regular maintenance therapy. By utilising a comprehen-
sive structured asthma review approach, the results of
this study helped to identify populations that should
be targeted by tailored interventions to improve prac-
tice. Moreover, this approach provided valuable insight
into patient behaviour regarding inhaler technique which
would have been impossible to obtain through other
approaches such as online surveys utilised in other studies
[13–20,24,25,27]. While many multinational studies have
shown that poor asthma control remains prevalent, few
studies have assessed asthma control in real-life clinical
practice and none in the Australian population, a popu-
lation with one of the highest asthma prevalence rates in
theworld (in 2015, therewere 2.4millionAustralianswith
a recorded diagnosis of asthma, i.e., 9.9% of the popula-
tion) [2]. This study focused on those patients with recent
general practice contact receiving combination preven-
ter therapy, this being the most highly prescribed asthma
medication type in Australia (prescribed in 49.5% of the
GP encounters among Australian adults with asthma in
2011, and almost five times the proportion of encounters
for asthma at which ICSs alone had been prescribed) [3].
Thus, the results of this study become highly relevant and
translatable into current practice.
In this study, asthma control was defined based on the
2011 GINA report [30]. This particular framework for
evaluating asthma control was used over other measures
(e.g. the Asthma Control Test (ACT)) [37] due to the fact
that it bases control assessment on symptoms and reliever
use, independent of patient’s perceptions of their level of
asthma control (a disadvantage of using the ACT which
has the potential to overestimate the level of asthma con-
trol based on the influence of patient’s perceptions). This
study revealed that in a population of patients with cur-
rent asthma, asthma control remains sub-optimal with
only 11.5% of the patients having controlled asthma as
defined by GINA guidelines, despite being prescribed a
combination therapy. A proportion of controlled patients
also had acute exacerbations, emergency department vis-
its and hospitalisations due to asthma over the previ-
ous year, increasing their future risk of exacerbation and
adverse asthma outcomes [4–6]. Compared with other
recent online surveys, the incidence of controlled asthma
in our real-world study was lower than that reported by
Reddel et al. using the ACT (54.7% had well-controlled
asthma) [20] and in online surveys using GINA-defined
criteria across Europe (20.1%) [24], Asia (17.8%) [25] and
Australia (12.0%) [15]. This clearly identifies a trend in
the Australian asthma cohort in which the incidence of
controlled asthma achieved seems to be lower than that
achieved internationally.
A major finding of this research is the lack of accurate
perception of poor control and tolerance of symptoms
on the part of the patient. Almost half of the patients
with uncontrolled asthma believed that they had well-
controlled asthma, even if they were symptomatic or
limited in their daily activities. This acceptance of symp-
toms as the ‘norm’may be due to low patient expectations,
which, in turn, may be as a result of poor clinical care
[27,38]. Almost half of the patients did not recognise
the nighttime symptoms and the overuse of reliever
medication as indicators of poor control, suggesting a
continuous discrepancy between patient’s perception
of control and guideline-defined control. This raises
questions about patients’ understanding of the concept
of asthma control, and factors being utilised by patients
to gauge their level of asthma control. These findings
are consistent with recent online surveys across Europe
[24,27], Asia [25] and Australia [15]. It has been well
documented that patients’ inaccurate estimation of their
level of asthma control can create a barrier to the attain-
ment of optimal asthma management [15,24,25,27,38].
Patients may benefit from a comprehensive structured
asthma review, which offers self-management education
including a written asthma action plan, self-monitoring
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8 S. BOSNIC-ANTICEVICH ET AL.
and regular medical review, to assist in addressing some
of these areas [5,27,39]. A personalised written asthma
action plan not only provides clear instructions on
what to do for worsening asthma, but is also an effec-
tive tool which can be used to educate patients about
the understanding of control and help raise patient’s
expectations. Future research into factors associated
with patient’s inaccurate perception of asthma control
and predictors of uncontrolled asthma also needs to be
investigated.
This study revealed that coexisting rhinitis was highly
prevalent, yet underreported and undertreated. There
was a discrepancy between diagnosis (49%) and preva-
lence (90%), with moderate–severe rhinitis symptoms
more common among uncontrolled asthma patients. Of
104 (57.8%) patients with moderate–severe rhinitis, 70
(67.3%) patients were not using first-line INCS therapy
[31]. Similar findings have been reported in a random
sample of aDanish population,where 49.0%of the asthma
patients had undiagnosed and untreated comorbid aller-
gic rhinitis (AR) [40]. Up to 80% of the Australians with
allergic asthma have coexisting AR and at least 30% with
known AR also have asthma [5]. Both AR and non-AR
are the risk factors for the development of asthma [31,41],
and pose a significant socioeconomic burden on the indi-
viduals and society [42]. Given that AR and asthma are
the manifestations of one chronic inflammatory process
in two parts of a single airway [43], and that untreated or
sub-optimally managed AR has been shown to be associ-
ated with worse asthma control [44], it is recommended
that HCPs screen all patients with asthma for AR (and
for asthma in AR patients). It is also recommended that
HCPs raise awareness of the asthma and AR link, and use
an integrated and unified approach in the management of
both conditions [31,41].
Another significant yet disappointing finding in this
study relates to the medication use. Despite the recom-
mendations of evidence-based guidelines developed for
primary care health providers [5], and the fact that this
patient cohort engages with medical care, the medica-
tion use has yet again been identified as problematic, in
terms of adherence, inhaler technique and patient under-
standing of the value of medicines and experiences of side
effects. In this study, adherence rates to inhaled preven-
ter therapy were low (41.0%), with uncontrolled asthma
patients more likely to take preventer medication spo-
radically. Interestingly, half of the patients had concerns
about taking regular preventer medication and almost
80.0% had experienced at least one side effect, possibly
contributing to their reduced willingness to use them,
and ultimately leading to poor control [26,45]. More-
over, not a single patient was able to demonstrate correct
inhaler technique, even though most patients believed
that their technique was satisfactory, highlighting the
disparity between patients’ perceptions and reality. The
results also demonstrate that poor adherence and poor
inhaler technique coexist [46], and that little progress
has been made in recent decades in improving patient
adherence and inhaler technique in asthma manage-
ment [15,20,27,36,47]. Our results strengthen the need to
address and regularly review factors which contribute to
poor asthma control before stepping-up treatment, those
whichmight influence patient adherence, includingmed-
ication side effects [48], and those which might influence
inhaler technique maintenance [46]. As the majority of
patients had not had their inhaler technique checked in
the past year, there is an urgent need for HCPs to recheck
the inhaler technique and provide education reinforced
regularly, as recommended by current asthma guidelines
[4,5], as well as intranasal device technique where appro-
priate [31,41].
There are some potential limitations to this study
which are associated with the convenience sampling
method, cross-sectional study design, and a reliance on
patient recall for self-reported symptoms, exacerbations
and medication behaviour that may have been under- or
overstated by patients. Additionally, even though there
were criteria to exclude people with COPD, and given
that many patients were aged 50 years or more with a
past or current smoking history (and at a greater risk of
COPD), it may have been possible that people with both
asthma and COPD were included and could have biased
the results. In considering the results of this research, it
is important to consider the patient population explored,
a patient cohort of moderate–severe asthma-prescribed
FDC ICS/LABA therapy, who had a recent GP contact
as opposed to patients with milder disease who may not
have a regular GP contact. However, there is a possibility
that patients regularly seeking a GP might also be those
who are not well controlled, thereby limiting the gener-
alisability of our results. There is also a possibility that
patients receiving FDC ICS/LABA therapy might have
milder disease and are being overtreated due to failure
in excluding poor inhaler technique, poor adherence or
comorbidities. Despite these limitations, this research
provided valuable insight by using a structured in-depth
asthma review approach, and helped identify popula-
tions that should be targeted and the type of interventions
needed in primary care, wheremost asthma ismanaged in
Australia.
Conclusions
The results from this study confirmed that even amongst
a cohort of adults with asthma who regularly seek care
from a GP, the proportion of individuals with controlled
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JOURNAL OF ASTHMA 9
asthma was extremely low and the medication use was
sub-optimal. The study revealed a consistent discrepancy
between patient’s perspectives and reality and their accep-
tance of asthma and rhinitis symptoms as well as med-
ication side effects. This research highlights the urgent
need for primary health practitioners to go back to basics
with their patients and raise patient expectations, com-
plete comprehensive reviews on an annual basis and bet-
ter support patients to self-management more effectively.
Not only there is a need for continuous education of
patients, but also education of health care practitioners to
better understand the way in which patient’s perceptions
impact on asthma management practices, incorporating
these findings into clinical decision making.
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